000 01301 a2200385 4500
005 20250514231828.0
264 0 _c20050913
008 200509s 0 0 eng d
022 _a0025-729X
024 7 _a10.5694/j.1326-5377.2005.tb06844.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aHall, Wayne D
245 0 0 _aTailoring access to high cost, genetically targeted drugs.
_h[electronic resource]
260 _bThe Medical journal of Australia
_cJun 2005
300 _a607-8 p.
_bdigital
500 _aPublication Type: Editorial
650 0 4 _aAdvisory Committees
650 0 4 _aAustralia
650 0 4 _aConfidentiality
650 0 4 _aCost-Benefit Analysis
650 0 4 _aDecision Making, Organizational
650 0 4 _aDrug Approval
650 0 4 _aDrug Costs
650 0 4 _aFinancing, Government
650 0 4 _aHealth Services Accessibility
_xeconomics
650 0 4 _aHumans
650 0 4 _aInsurance, Pharmaceutical Services
_xeconomics
650 0 4 _aPharmacogenetics
700 1 _aWard, Robyn
700 1 _aLiauw, Winston S
700 1 _aLu, Christine Y
700 1 _aBrien, Jo-anne E
773 0 _tThe Medical journal of Australia
_gvol. 182
_gno. 12
_gp. 607-8
856 4 0 _uhttps://doi.org/10.5694/j.1326-5377.2005.tb06844.x
_zAvailable from publisher's website
999 _c15621528
_d15621528